Mergers and Acquisitions Mergers


  • Australia's competition watchdog said Royal Dutch Shell's $70B takeover of BG Group would not change the domestic natural gas market.

  • Syngenta is just fine alone: Analyst

    Christian Faitz, equity research analyst at Kepler Cheuvreux, explains why Monsanto’s bid to buy Syngenta was more than just the price.

  • John Malone

    Liberty Media chief John Malone said he wouldn't be surprised to see more media consolidation as global scale becomes important.

  • Anheuser Busch finalizes deal for SABMiller

    Anheuser-Busch InBev completed an agreement to acquire SABMiller for about $105 billion.

  • Bottles of SABMiller's Miller Lite and Anheuser-Busch InBev's Budweiser beer.

    AB InBev is poised to announce on Wednesday that it has clinched a deal to buy SABMiller for £68 billion, the Financial Times reports.

  • Dell and EMC

    Dell's ambitious plan to take over storage giant EMC may face a tax burden that could derail the deal. Re/code reports.

  • Mega deals in the spotlight

    David Solomon, Goldman Sachs, weighs in on this year's blockbuster M&A deals and provides a look at what to expect into 2016. Also Solomon discusses plans to keep junior bankers at the firm longer.

  • Qube takes on Brookfield with $6.3B Asciano bid

    Alex Leyland, portfolio manager at Leyland Private Asset Management, discusses whether Qube or Brookfield stands a better chance of acquiring Australia's Asciano.

  • Tablets of over-the-counter allergy medicines, manufactured by Perrigo Co.

    Some of those generic pills you buy at the drug store could change ownership Friday.

  • Mobile phone

    Forrester predicts the mobile revolution will accelerate in 2016. Who are the winners?

  • Developing M&A culture: Ken Moelis

    Ken Moelis, Moelis & Co. founder & CEO, talks about the art of dealmaking and current trends in M&A. And Ron Baron, Baron Capital chairman & CEO, weighs in.

  • DuPont holding talks with Syngenta and Dow Chemical

    DuPont is holding talks with Syngenta and Dow Chemical for a potential deal, as the agriculture world struggles with lower crop prices and profits.

  • AstraZeneca acquires ZS Pharma

    Peter Toogood, investment director at City Financial Investment Company Limited, explains why large pharmaceuticals tend to take over midcap rivals.

  • Characters from King Digital Entertainment "Candy Crush" game stand for a photograph in front of a trading post on the floor of the New York Stock Exchange, March 26, 2014.

    Activision Blizzard announced the company would acquire King Digital for $5.9 billion. Here's the user habits that make it such a valuable acquisition.

  • Visa Europe deal makes strategic sense: Pro

    Kevin McVeigh, managing director and head of U.S. financials at Macquarie Capital, explains why he believes Visa will announce that it will buy Visa Europe on Monday.

  • Are mergers ahead in airline industry?

    Michael O'Leary, CEO of Ryanair, says he prefers organic growth to M&A.

  • Aviva: This friendly deal is delivering value

    Chris Wei, executive chairman for Asia at Aviva, says the acquisition of Friends Life this year has brought new business growth and improved synergies.

  • Allergan, Pfizer in friendly negotiations

    CNBC's David Faber has the update on a potential deal between drugmakers Pfizer and Allergan on the floor of the NYSE.

  • Pfizer and Allergan in preliminary talks

    "Squawk on the Street" David Faber has the update on a potential deal between drugmakers Pfizer and Allergan and the tax benefits that would follow.

  • Pfizer and Allergan talk merger

    Pharmaceutical giants Pfizer and botox maker Allergan are in discussions about a potential takeover deal.